PB2251 A PHASE II, OPEN-LABEL, PROSPECTIVE STUDY (TAPER) TO ASSESS THE ABILITY OF ELTROMBOPAG TO INDUCE SUSTAINED TREATMENT-FREE REMISSION IN ITP PATIENTS WITH INSUFFICIENT RESPONSE TO CORTICOSTEROIDS - KIVIRID

PB2251 A PHASE II, OPEN-LABEL, PROSPECTIVE STUDY (TAPER) TO ASSESS THE ABILITY OF ELTROMBOPAG TO INDUCE SUSTAINED TREATMENT-FREE REMISSION IN ITP PATIENTS WITH INSUFFICIENT RESPONSE TO CORTICOSTEROIDS

Authors: N. Cooper, W. Ghanima, J. Haenig, J. Jha, J. Lee, F. Zaja

Published: 2019-06-17

DOI: 10.1097/01.hs9.0000567480.47134.f7

Source: Full article

Abstract

No abstract found.